November 2008 Cover
|
 |
We are starting a "dry period" in HIV drug approvals that will last around three years, so for those of us who have failed Fuzeon, raltegravir and have X4 tropic virus, very few drug will be coming our way.
Tanox, a company that was bought out by Genetech, has an intravenous drug (a monoclonal antibody) that will start phase II studies in a few weeks. That is about all we have as a new agent for multi-drug resistant virus.
We just went through a wave of new drug approvals last year. Raltegravir, maraviroc and TMC-125 (a non-nuke) were approved. But a few patients already have raltegravir resistance. Our main job as activists is to remind companies that we exist and that there will be a need for better drugs in the future.
Gene therapy and stem cell research are also true hopes to change the nature of how we treat HIV.
from TheBody.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
